Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
FABP1 encodes the fatty acid binding protein found in liver. Additionally we are shipping FABP1 Kits (56) and FABP1 Proteins (39) and many more products for this protein.
Showing 10 out of 163 products:
Human Monoclonal FABP1 Primary Antibody for WB - ABIN396611
Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. in Diabetes Care 2010
Show all 5 references for ABIN396611
Human Monoclonal FABP1 Primary Antibody for EIA, IHC (p) - ABIN317518
Atshaves, Storey, Huang, Schroeder: Liver fatty acid binding protein expression enhances branched-chain fatty acid metabolism. in Molecular and cellular biochemistry 2004
Show all 2 references for ABIN317518
Baboon Monoclonal FABP1 Primary Antibody for EIA, IHC (fro) - ABIN1107159
Bax, Siersema, Haringsma, Kuipers, Vos, Van Dekken, Van Vliet, Kusters: High-grade dysplasia in Barrett's esophagus is associated with increased expression of calgranulin A and B. in Scandinavian journal of gastroenterology 2007
Human Polyclonal FABP1 Primary Antibody for IHC, WB - ABIN2782982
Yamada, Kato, Oguri, Yoshida, Yokoi, Watanabe, Metoki, Yoshida, Satoh, Ichihara, Aoyagi, Yasunaga, Park, Tanaka, Nozawa: Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. in International journal of molecular medicine 2008
Urinary L-FABP appears to be a sensitive biomarker of acute kidney injury in patients undergoing abdominal aortic repair.
Urinary levels of NGAL (show LCN2 Antibodies) are more sensitive than uKIM-1 and uL-FABP (show FABP2 Antibodies) levels in predicting renal scarring in vesicoureteral reflux.
Loss of staining for LFABP appears to be common in hepatocellular carcinoma and may be seen in well-differentiated hepatocellular carcinoma.
In this study, the effects of hepatitis B virus X protein (HBx) mediated FABP1 regulation on hepatic steatosis and the underlying mechanism were determined.
compared with the rs2919872 G allele, the rs2919872 A allele reduces the transcriptional activity of FABP1 promoter, and thereby may link FABP1 gene variation to triglyceride level in humans.
Higher urinary L-FABP was found in pregnant with and without gestational diabetes mellitus(GDM), and considerably higher urinary L-FABP was found in the GDM group compared with the non-GDM group.
Multivariable regression analysis revealed that urinary L-FABP and urinary albumin (show ALB Antibodies)/ creatinine ratio were significantly associated with urinary ACE2 (show ACE2 Antibodies) levels.
Measurement of uL-FABP (show FABP2 Antibodies) levels at 48 h after coronary angiography may be useful in detecting renal damage, and in predicting 1-year renal outcome in ischemic heart disease patients undergoing CAG.
Measurement of urinary L-FABP and albumin (show ALB Antibodies)/creatinine ratio should be useful to assess cardiovascular damage reflecting the elevation of cardiac markers and ECG abnormalities in T2DM with CKD.
Urinary L-FABP is strongly associated with anemia in non-diabetic patients.
L-FABP was more important in hepatic retention of bile acids, while SCP-2/SCP-x (show SCP2 Antibodies) more broadly affected biliary bile acid and phospholipid levels.
These findings suggest that some of the phenotypic divergence between the two L-Fabp(-/-) lines may reflect unanticipated differences in genetic background, underscoring the importance of genetic background in phenotypic characterization.
Loss of L-FABP and SCP-2 (show CRISP3 Antibodies), or both induces hepatic lipid accumulation in female mice and mimics non-alcoholic fatty liver disease.
L-FABP appears to function more in hepatic retention of bile acids as well as hepatic uptake and biliary secretion of HDL (show HSD11B1 Antibodies)-cholesterol
L-FABP is not required to channel ATGL (show PNPLA2 Antibodies)-hydrolyzed FAs (show FAS Antibodies) to mitochondria for beta-oxidation or the nucleus for PPAR-alpha (show PPARA Antibodies) regulation
Data show that combined deletion of microsomal triglyceride transfer protein (Mttp (show MTTP Antibodies)) and liver fatty acid binding protein 1 (L-Fabp) are protected from lithogenic diet (LD)-induced gallstone formation.
L-Fabp has a role in modifying intestinal fatty acid composition and adenoma formation in ApcMin/+ mice
The maximum increase in LFABP expression occurs when stimulation with IL-6 (show IL6 Antibodies) and PPARalpha (show PPARA Antibodies)-ligands takes place simultaneously.
This direct comparison provides evidence that LFABP and IFABP (show FABP2 Antibodies) have distinct roles in intestinal lipid metabolism; differential intracellular functions in intestine and in liver
liver-type fatty acid-binding protein in the proximal tubules may protect against angiotensin II-induced SSHT by attenuating activation of the intrarenal renin (show REN Antibodies)-angiotensin system and reducing oxidative stress and tubulointerstitial inflammation.
This gene encodes the fatty acid binding protein found in liver. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. This protein and FABP6 (the ileal fatty acid binding protein) are also able to bind bile acids. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism.
fatty acid binding protein 1, liver
, fatty acid-binding protein, liver
, fafatty acid binding protein 1, liver
, fatty acid-binding protein 1
, liver-type fatty acid-binding protein
, 14 kDa selenium-binding protein
, fatty acid binding protein liver
, squalene- and sterol-carrier protein
, fatty acid-binding protein
, liver fatty acid binding protein
, liver basic FABP
, liver bile acid-binding protein